×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Thyroid Cancer

Jessica Skarzynski
For Thyroid Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
Kristi Rosa
Progress in treating rare cancers represents the most significant oncology advance of last year, ASCO says.
Arlene Weintraub
A new drug can break the circuit of cancer-causing effects that develop when certain genes fuse.
Carly Flumer
Cancer doesn’t discriminate. It doesn’t care what race, gender, ethnicity, sexuality or even age you are. It takes no prisoners. And it certainly did not take me. I continue to remain resilient despite what I’ve been through and despite what still may be on the horizon.
Alexandra Guadagno
From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.
Carly Flumer
As a result of what I went through and my never-ending passion for helping others, I believe that my diagnosis happened for a reason – to lead me to a career in patient advocacy.
Katie Kosko
Survivor diagnosed with second cancer after surgeon spots a lump on her throat while watching TV.
Gina Columbus
The Food and Drug Administration has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor.
Silas Inman
The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.
MIKE HENNESSY, SR.
From genetic mutations to treatment behind bars, here's a roundup of our 2018 Summer issue.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×